Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STRO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSutro Biopharma shareholders approve routine annual meeting matters, elect three directors
Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
low
Shareholders elected Jane Chung, Connie Matsui, and James Panek as Class II directors for three-year terms expiring in 2029, with all three receiving majority support.
Item 5.07 verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for fiscal 2026 with overwhelming approval (13.9M shares for vs. 501 against).
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with strong shareholder support (11.3M for vs. 22K against), indicating satisfaction with current pay practices.
Item 5.07 verify on EDGAR →
Summary
Sutro Biopharma held its 2026 Annual Meeting on June 5, where shareholders voted on standard corporate governance matters. The company successfully elected three Class II directors to serve until 2029, ratified its auditor selection, and received strong approval for executive compensation practices. All proposals passed with substantial majorities, reflecting routine shareholder support.
For retail investors, this filing represents standard annual meeting business with no material changes to company operations, strategy, or financial outlook. The strong vote counts across all proposals suggest no significant shareholder dissent or governance concerns. Watch for the company's next quarterly earnings report for updates on business performance and pipeline progress, as this procedural filing provides no operational insights.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify